V 710

Drug Profile

V 710

Alternative Names: 0657nI Staphylococcus aureus vaccine - Merck; S.aureus vaccine - Merck; Staphylococcus aureus vaccine - Merck; V-710

Latest Information Update: 10 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intercell
  • Developer Merck & Co
  • Class Bacterial vaccines; Surface antigens
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 09 Jun 2011 Merck and Intercell terminate their phase II/III trial in Staphylococcal infections in USA, European Union, Asia and South America due to efficacy concerns (NCT00518687)
  • 18 Apr 2011 Merck and Intercell suspend their phase II/III trial in Staphylococcal infections in USA, European Union, Asia and South America (NCT00518687)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top